$45.05
+1.23
(+2.81%)▲
Insights on Crinetics Pharmaceuticals Inc
Revenue is down for the last 3 quarters, 2.67M → 346.0K (in $), with an average decrease of 64.1% per quarter
Netprofit is down for the last 6 quarters, -40.39M → -60.09M (in $), with an average decrease of 8.4% per quarter
In the last 3 years, Novo Nordisk A/s has given 247.0% return, outperforming this stock by 93.9%
3.07%
Downside
Day's Volatility :4.83%
Upside
1.81%
65.02%
Downside
52 Weeks Volatility :68.21%
Upside
9.14%
Period | Crinetics Pharmaceuticals Inc | Sector (Health Care) | Index (Russel 2000) |
---|---|---|---|
3 Months | 17.76% | -1.3% | 0.0% |
6 Months | 48.29% | 12.4% | 0.0% |
1 Year | 113.76% | 4.6% | 0.0% |
3 Years | 150.26% | 15.7% | -21.9% |
Market Capitalization | 3.3B |
Book Value | $7.91 |
Earnings Per Share (EPS) | -3.69 |
Wall Street Target Price | 57.92 |
Profit Margin | 0.0% |
Operating Margin TTM | -5547.17% |
Return On Assets TTM | -28.18% |
Return On Equity TTM | -50.16% |
Revenue TTM | 4.0M |
Revenue Per Share TTM | 0.07 |
Quarterly Revenue Growth YOY | -100.0% |
Gross Profit TTM | -125.5M |
EBITDA | -221.5M |
Diluted Eps TTM | -3.69 |
Quarterly Earnings Growth YOY | 0.0 |
EPS Estimate Current Year | -3.29 |
EPS Estimate Next Year | -3.54 |
EPS Estimate Current Quarter | -0.86 |
EPS Estimate Next Quarter | -0.87 |
What analysts predicted
Upside of 28.57%
Sell
Neutral
Buy
Crinetics Pharmaceuticals Inc is currently in a favorable trading position ( BUY ) according to technical analysis indicators.
Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
---|---|---|---|---|---|
Crinetics Pharmaceuticals Inc | -5.82% | 48.29% | 113.76% | 150.26% | 70.37% |
Moderna, Inc. | 4.46% | 44.76% | -17.31% | -40.7% | 317.84% |
Regeneron Pharmaceuticals, Inc. | -8.11% | 12.56% | 10.41% | 82.28% | 161.35% |
Novo Nordisk A/s | 0.6% | 31.36% | 53.28% | 240.62% | 422.33% |
Vertex Pharmaceuticals Incorporated | -6.58% | 6.36% | 13.86% | 80.23% | 127.58% |
Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
---|---|---|---|---|---|---|---|---|
Crinetics Pharmaceuticals Inc | NA | NA | NA | -3.29 | -0.5 | -0.28 | NA | 7.91 |
Moderna, Inc. | 24.73 | NA | 0.0 | -7.22 | -0.29 | -0.12 | NA | 36.27 |
Regeneron Pharmaceuticals, Inc. | 26.04 | 26.04 | 1.46 | 45.0 | 0.16 | 0.08 | NA | 242.47 |
Novo Nordisk A/s | 47.43 | 47.43 | 2.4 | 3.35 | 0.88 | 0.23 | 0.01 | 23.9 |
Vertex Pharmaceuticals Incorporated | 28.81 | 28.81 | 0.53 | 16.75 | 0.23 | 0.13 | NA | 68.22 |
Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
---|---|---|---|---|---|
Crinetics Pharmaceuticals Inc | Buy | $3.3B | 70.37% | NA | 0.0% |
Moderna, Inc. | Buy | $41.7B | 317.84% | 24.73 | -68.84% |
Regeneron Pharmaceuticals, Inc. | Buy | $99.5B | 161.35% | 26.04 | 30.14% |
Novo Nordisk A/s | Buy | $562.8B | 422.33% | 47.43 | 36.03% |
Vertex Pharmaceuticals Incorporated | Buy | $103.6B | 127.58% | 28.81 | 36.68% |
BlackRock Inc
Driehaus Capital Management LLC
Point72 Asset Management, L.P.
FMR Inc
State Street Corporation
Vanguard Group Inc
Crinetics Pharmaceuticals Inc’s price-to-earnings ratio stands at None
Read Moreneuropeptide receptor targeted therapeutics for the treatment of endocrine diseases and cancers. we are driven by a passion for drug-hunting and tempered by a post-recession startup culture. our goal is to create new therapeutics that can make a meaningful difference in the lives of our patients.
Organization | Crinetics Pharmaceuticals Inc |
Employees | 290 |
CEO | Dr. R. Scott Struthers Ph.D. |
Industry | Health Technology |
Sasol Ltd.
$45.05
+2.81%
Dimensional Us Core Equity M
$45.05
+2.81%
Tenet Healthcare Corp.
$45.05
+2.81%
Paycor Hcm Inc
$45.05
+2.81%
Icahn Enterprises, L.p.
$45.05
+2.81%
Immunocore Holdings Plc-adr
$45.05
+2.81%
Jpmorgan Betabuilders Us Equ
$45.05
+2.81%
Newmarket Corporation
$45.05
+2.81%
California Resources Corp
$45.05
+2.81%